A new clinical-stage company with plans to develop therapies for neuropsychiatric disorders was launched in the UK on 18 June on the back of $140 million in Series A financing led by Access Biotechnology, the investment arm of Access Industries. The company, Draig Therapeutics Ltd, is an academic spin-out which capitalises on scientific discoveries made by two professors at Cardiff University in Wales.